Physician profile
Jada Pascual
NPI 1639955230
$5,083.39
in general payments reported to CMS, 2019-2025
23 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $573 · 2024: $3,799 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,023 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.40 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,596.91 | 2023-2025 | |
| Amgen INC. | $653.26 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Glaxosmithkline, LLC. | $561.49 | 2023-2025 | Benlysta |
| Ucb, INC. | $306.95 | 2024-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $241.86 | 2023-2024 | Taltz, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $220.72 | 2023-2025 | Tremfya |
| Radius Health, INC. | $220.09 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $198.16 | 2023-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $165.18 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $159.25 | 2023-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.24 | 2024-2025 | Ofev |
| Kiniksa Pharmaceuticals International, Plc | $108.09 | 2024 | Arcalyst |
| Pfizer INC. | $106.83 | 2024-2025 | |
| Fidia Pharma USA INC. | $86.47 | 2024 | Hymovis, Hyalgan, Triluron |
| Aurinia Pharma U.S., INC. | $74.95 | 2024 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.43 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $62.34 | 2024 | Idacio |
| Scilex Pharmaceuticals INC. | $49.87 | 2024 | |
| Genzyme Corporation | $23.14 | 2024 | |
| Sobi, INC | $19.34 | 2024 | |
| Zimmer Biomet Holdings, INC. | $16.60 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Octapharma USA, INC. | $15.16 | 2024 | Octagam Immune Globulin (Human) |
| Teva Pharmaceuticals USA, INC. | $15.06 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jada Pascual listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.